Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 207-951-2 | CAS number: 502-72-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- other: toxicokinetic assessment based on all available information
- Adequacy of study:
- key study
- Study period:
- March 2018
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: expert statement based on analysis of all available information
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- Expert statement based on the analysis of all available information on the substance, including physico-chemical properties and the results of toxicological studies.
- GLP compliance:
- no
- Radiolabelling:
- no
- Species:
- other: not applicable, toxicokinetic assessment
- Type:
- absorption
- Results:
- For risk assessment purposes, 100% absorption will be considered for oral and respiratory exposure; 50% absorption will be considered for dermal route.
- Type:
- distribution
- Results:
- The substance is metabolized in the liver and can be distributed through the body.
- Type:
- metabolism
- Results:
- The substance is likely to be metabolized in the liver.
- Type:
- excretion
- Results:
- The substance is likely to be excreted via urine.
- Details on absorption:
- The results of the available 28-day study with the reproductive and developmental toxicity screening suggest that the substance can be absorbed by oral route. Adverse toxicological effects were observed following the substance administration by gavage. For risk assessment purposes, 100% oral absorption will be considered in the lack of other data. The substance has a high log Kow (range 3.3-5.6, the main constituent has most probably the log Kow of 5.6), but its molecular weight is below the cut-off value of 500 g/mol. However, the substance is not irritating and not sensitizing, and its very low solubility and high log Pow suggests that it will not partition readily from stratum corneum into the epidermis. Therefore the value of 100% is considered to be overly conservative, and in the absence of other data the value of 50% will be used for dermal absorption. Cyclopentanone is a paste with a low vapour pressure (< 0.4 Pa, value probably overestimated, as it was obtained from the melting point study), thus respiratory exposure to the substance is considered to be very unlikely. However, as a worst case approach, 100% respiratory absorption will be considered in the risk assessment.
- Details on distribution in tissues:
- Based on the results of the available 28-day study with reproductive and developmental toxicity screening, in which adverse effects on the liver and kidneys were seen, following oral absorption the substance is transported to liver where it is probably metabolized and is subsequently excreted into urine via kidneys. As toxicological effects were observed in several organs and tissues, it is possible that the metabolites are distributed through the body after entering the systemic cirtulation. Based on physico-chemical properties of the substance, i.e. high log Kow, some degree of accumulation of the non-metabolized substance in adipose tissue cannot be excluded.
- Details on excretion:
- Based on the results of the available 28-day study with reproductive and developmental toxicity screening, in which adverse effects on kidneys were observed, the substance is probably removed by kidneys and is subsequently excreted in urine.
- Metabolites identified:
- no
- Details on metabolites:
- Based on Toxtree v 2.6.13 prediction for CYP450-mediated metabolism, the primary site for metabolic conversion is an aliphatic hydroxylation of the CH2 group in the alpha-position of the ketone group, while the secondary site is the aliphatic hydroxylation at C8 and C9 carbon atoms. It is possible that the generated hydroxyl groups are subsequently glucuronidated in the liver, which will increase the water solubility.
- Conclusions:
- The toxicokinetic assessment for cyclopentadecanone was performed based on all available data. For risk assessment purposes, 100% absorption is considered for oral and respiratory routes of exposure, and 50% absorption is considered for dermal route. Based on the results of the available 28-day toxicity study, following oral absorption the substance is probably transported to liver, where it undergoes metabolization, with subsequent excretion into urine via kidneys. Based on physico-chemical properties of the substance, some degree of accumulation in adipose tissue cannot be excluded.
- Executive summary:
The toxicokinetic assessment for cyclopentadecanone was performed based on all available data. The results of the available 28-day study with the reproductive and developmental toxicity screening suggest that the substance can be absorbed by oral route. Adverse toxicological effects were observed following the substance administration by gavage. For risk assessment purposes, 100% oral absorption will be considered in the lack of other data. The substance has a high log Kow (range 3.3-5.9, the main constituent has most probably the log Kow of 5.6), but its molecular weight is below the cut-off value of 500 g/mol. However, based on the very low solubility of the substance and its high log Pow, the value of 50% will be used for dermal absorption. Cyclopentadecanone is a paste with a low vapour pressure (< 0.4 Pa, value probably overestimated, as it was obtained from the melting point study), thus respiratory exposure to the substance is considered to be very unlikely. However, as a worst case approach, 100% respiratory absorption will be considered in the risk assessment. Based on the results of the available 28-day study with reproductive and developmental toxicity screening, in which adverse effects on the liver and kidneys were seen, following oral absorption the substance is transported to liver where it is probably metabolized and is subsequently excreted into urine via kidneys. Based on Toxtree v 2.6.13 prediction for CYP450-mediated metabolism, the primary site for metabolic conversion is an aliphatic hydroxylation of the CH2group in the alpha-position of the ketone group, while the secondary site is the aliphatic hydroxylation at C8 and C9 carbon atoms. As toxicological effects were observed in several organs and tissues, it is possible that the substance and/or its metabolites are distributed through the body after entering the systemic cirtulation. Based on physico-chemical properties of the substance, i.e. high log Kow, some degree of accumulation of the non-metabolized substance in adipose tissue cannot be excluded.
Reference
Description of key information
The toxicokinetic assessment for cyclopentadecanone was performed based on all available data. For risk assessment purposes, 100% absorption is considered for oral and respiratory routes of exposure, and 50% absorption is considered for dermal route. Based on the results of the available 28-day toxicity study, following oral absorption the substance is probably transported to liver, where it undergoes metabolization, with subsequent excretion into urine via kidneys. Based on physico-chemical properties of the substance, some degree of accumulation of the non-metabolized substance in adipose tissue cannot be excluded.
Key value for chemical safety assessment
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
The toxicokinetic assessment for cyclopentadecanone was performed based on all available data. The results of the available 28-day study with the reproductive and developmental toxicity screening suggest that the substance can be absorbed by oral route. Adverse toxicological effects were observed following the substance administration by gavage. For risk assessment purposes, 100% oral absorption will be considered in the lack of other data. The substance has a high log Kow (range 3.3-5.9, the main constituent has most probably the log Kow of 5.6), but its molecular weight is below the cut-off value of 500 g/mol. However, based on the very low solubility of the substance and its high log Pow, the value of 50% will be used for dermal absorption. Cyclopentadecanone is a paste with a low vapour pressure (< 0.4 Pa, value probably overestimated, as it was obtained from the melting point study), thus respiratory exposure to the substance is considered to be very unlikely. However, as a worst case approach, 100% respiratory absorption will be considered in the risk assessment. Based on the results of the available 28-day study with reproductive and developmental toxicity screening, in which adverse effects on the liver and kidneys were seen, following oral absorption the substance is transported to liver where it is probably metabolized and is subsequently excreted into urine via kidneys. Based on Toxtree v 2.6.13 prediction for CYP450-mediated metabolism, the primary site for metabolic conversion is an aliphatic hydroxylation of the CH2 group in the alpha-position of the ketone group, while the secondary site is the aliphatic hydroxylation at C8 and C9 carbon atoms. As toxicological effects were observed in several organs and tissues, it is possible that the substance and/or its metabolites are distributed through the body after entering the systemic cirtulation. Based on physico-chemical properties of the substance, i.e. high log Kow, some degree of accumulation of the non-metabolized substance in adipose tissue cannot be excluded.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.